BUPHENYL POWDER Rx
Generic Name and Formulations:
Sodium phenylbutyrate 940mg/gram; contains sodium 11.7g/100g of pwd.
Indications for BUPHENYL POWDER:
Adjunct in the chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase, including neonatal-onset deficiency and late-onset disease with a history of hyperammonemic encephalopathy.
Adults and Children:
<20kg: use powder. Take in equally divided doses with each meal or feeding. Mix powder with food or liquid. <20kg: 450–600mg/kg/day. ≥20kg: 9.9–13g/m2/day. Max 20g/day.
Restrict dietary protein, may need to supplement with essential amino acids. CHF. Sodium retention with edema. Renal or hepatic insufficiency. Inborn errors of beta oxidation. Monitor serum levels of phenylbutyrate and metabolites, phenylacetate and phenylacetylglutamine. Plasma levels of ammonia, arginine, branched-chain amino acids, serum proteins: maintain within normal levels; plasma glutamine: maintain at <1000μmol/L. Elderly. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by probenecid. Corticosteroids may increase plasma ammonia levels. Hyperammonemia possible with haloperidol and valproic acid.
Amenorrhea/menstrual dysfunction, acidosis, hypoalbuminemia, anemia, alkalosis, hyperchloremia, hypophosphatemia, increased alkaline phosphatase, increased liver transaminases, leukopenia, leukocytosis, decreased appetite, body odor, bad taste, taste aversion, others.
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Chronic Spinal Pain and Depression: Does One Represent a Risk Factor for the Other?
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Persistence of Post-Traumatic CRPS Associated With Initial Pain Sensitization
- Comparable Incidence, Intensity of Tourniquet Pain With Infraclavicular, Axillary Brachial Plexus Blocks
- Many Patients Withhold Information From Clinicians
- Shifting Pattern Seen for Primary Care Office Visits
- Questionnaire Reliably Predicts Effect of Migraine on Work-Related Duties
- Clinicians Must Do Their Part to Address Inaccurate Online Health Information